Market Closed -
Nasdaq
04:00:00 2024-07-12 pm EDT
|
5-day change
|
1st Jan Change
|
0.4548
USD
|
+3.74%
|
|
+41.02%
|
-16.29%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
970.4
|
2,207
|
1,093
|
514.6
|
96.35
|
94.38
|
-
|
-
|
Enterprise Value (EV)
1 |
958.6
|
1,566
|
627.8
|
207.1
|
15.35
|
94.38
|
94.38
|
94.38
|
P/E ratio
|
-9.85
x
|
-17.3
x
|
-6.1
x
|
-2.51
x
|
-0.37
x
|
-0.87
x
|
-2.56
x
|
-3.34
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.47
x
|
18.7
x
|
9.87
x
|
4.62
x
|
0.55
x
|
2.8
x
|
1.24
x
|
0.99
x
|
EV / Revenue
|
9.47
x
|
18.7
x
|
9.87
x
|
4.62
x
|
0.55
x
|
2.8
x
|
1.24
x
|
0.99
x
|
EV / EBITDA
|
-9.58
x
|
-17.8
x
|
-6.28
x
|
-2.72
x
|
-0.93
x
|
-0.83
x
|
-1.91
x
|
-23
x
|
EV / FCF
|
-5.87
x
|
14.3
x
|
-4.26
x
|
-2.11
x
|
-0.39
x
|
-0.89
x
|
-2.49
x
|
-41
x
|
FCF Yield
|
-17%
|
7%
|
-23.5%
|
-47.4%
|
-255%
|
-113%
|
-40.2%
|
-2.44%
|
Price to Book
|
2.17
x
|
4.21
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
115,938
|
141,441
|
145,675
|
163,880
|
177,347
|
207,510
|
-
|
-
|
Reference price
2 |
8.370
|
15.60
|
7.500
|
3.140
|
0.5433
|
0.4548
|
0.4548
|
0.4548
|
Announcement Date
|
2/28/20
|
2/24/21
|
2/24/22
|
2/22/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
102.4
|
118.2
|
110.7
|
111.3
|
176.2
|
33.73
|
76.33
|
95.32
|
EBITDA
1 |
-101.2
|
-123.9
|
-173.9
|
-189.2
|
-103.9
|
-113.4
|
-49.35
|
-4.1
|
EBIT
1 |
-105.2
|
-129.6
|
-183.3
|
-201.3
|
-274
|
-121.3
|
-48.75
|
-50.92
|
Operating Margin
|
-102.69%
|
-109.61%
|
-165.61%
|
-180.85%
|
-155.48%
|
-359.49%
|
-63.86%
|
-53.42%
|
Earnings before Tax (EBT)
1 |
-95.42
|
-120.8
|
-178
|
-191.8
|
-262.9
|
-113.5
|
-42.32
|
-42.66
|
Net income
1 |
-95.19
|
-121
|
-178.3
|
-192.3
|
-257.8
|
-113.7
|
-39.13
|
-40.76
|
Net margin
|
-92.93%
|
-102.37%
|
-161.05%
|
-172.76%
|
-146.3%
|
-337.01%
|
-51.27%
|
-42.76%
|
EPS
2 |
-0.8500
|
-0.9000
|
-1.230
|
-1.250
|
-1.480
|
-0.5240
|
-0.1779
|
-0.1360
|
Free Cash Flow
1 |
-165.3
|
154.5
|
-256.5
|
-243.8
|
-246
|
-106.2
|
-37.9
|
-2.3
|
FCF margin
|
-161.42%
|
130.68%
|
-231.73%
|
-219.05%
|
-139.59%
|
-314.82%
|
-49.65%
|
-2.41%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
2/24/21
|
2/24/22
|
2/22/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
27.99
|
28.23
|
29.38
|
26.46
|
27.23
|
158
|
6.835
|
9.398
|
2.042
|
0.481
|
6.883
|
7.267
|
19.2
|
12
|
13
|
EBITDA
1 |
-37.14
|
-42.43
|
-42.85
|
-51.84
|
-52.05
|
80.09
|
-67.97
|
-56.12
|
-59.94
|
-50.13
|
-34.5
|
-34.6
|
20.3
|
-
|
-
|
EBIT
1 |
-39.9
|
-45.26
|
-45.73
|
-54.89
|
-55.39
|
76.6
|
-72.22
|
-61.61
|
-62.06
|
-51.53
|
-31.77
|
-28
|
-11.6
|
-19
|
-18
|
Operating Margin
|
-142.57%
|
-160.32%
|
-155.67%
|
-207.46%
|
-203.42%
|
48.5%
|
-1,056.69%
|
-655.55%
|
-3,039.13%
|
-10,712.27%
|
-461.5%
|
-385.32%
|
-60.42%
|
-158.33%
|
-138.46%
|
Earnings before Tax (EBT)
1 |
-37.56
|
-43.92
|
-43.09
|
-53.12
|
-51.71
|
21.33
|
-120.8
|
-102.9
|
-60.57
|
-48.99
|
-29.85
|
-26.33
|
-9.733
|
-16
|
-15
|
Net income
1 |
-37.5
|
-43.98
|
-43.17
|
-53.16
|
-51.97
|
21.13
|
-114.5
|
-104.2
|
-60.3
|
-49.09
|
-29.85
|
-26.33
|
-9.733
|
-16
|
-15
|
Net margin
|
-133.98%
|
-155.78%
|
-146.96%
|
-200.89%
|
-190.87%
|
13.38%
|
-1,675.29%
|
-1,108.35%
|
-2,952.79%
|
-10,205.61%
|
-433.66%
|
-362.39%
|
-50.69%
|
-133.33%
|
-115.38%
|
EPS
2 |
-0.2600
|
-0.3000
|
-0.2900
|
-0.3400
|
-0.3200
|
0.1200
|
-0.6600
|
-0.5900
|
-0.3400
|
-0.2700
|
-0.1463
|
-0.1290
|
-0.0250
|
-0.0700
|
-0.0700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/22/23
|
5/8/23
|
8/8/23
|
11/1/23
|
3/13/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
11.8
|
641
|
465
|
307
|
81
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-165
|
154
|
-257
|
-244
|
-246
|
-106
|
-37.9
|
-2.3
|
ROE (net income / shareholders' equity)
|
-23.8%
|
-26%
|
-40.8%
|
-57.4%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-15.5%
|
-15.4%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
614
|
788
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
3.860
|
3.710
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
1.260
|
-1.610
|
-1.450
|
-
|
-
|
-
|
-
|
Capex
1 |
20.9
|
14.7
|
23.3
|
20.2
|
21.2
|
11.3
|
10
|
8.5
|
Capex / Sales
|
20.44%
|
12.45%
|
21.03%
|
18.12%
|
12%
|
33.35%
|
13.1%
|
8.92%
|
Announcement Date
|
2/28/20
|
2/24/21
|
2/24/22
|
2/22/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
0.4548
USD Average target price
3.8
USD Spread / Average Target +735.53% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.29% | 94.38M | | +20.12% | 126B | | +25.25% | 119B | | +25.56% | 27.95B | | -19.51% | 20.5B | | -14.36% | 17.12B | | -15.63% | 16.1B | | -46.67% | 14.97B | | +11.89% | 14.84B | | +57.74% | 14.38B |
Bio Therapeutic Drugs
|